Profound Medical Competitors

Cardiovascular Systems (NASDAQ:CSII) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Cardiovascular Systems and Profound Medical's revenue, earnings per share (EPS) and valuation.

Profound Medical has lower revenue, but higher earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.7% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 35.9% of Profound Medical shares are held by institutional investors. 3.0% of Cardiovascular Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cardiovascular Systems and Profound Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Cardiovascular Systems and Profound Medical, as provided by MarketBeat.com.

Cardiovascular Systems presently has a consensus target price of $47.5714, indicating a potential upside of 22.76%. Profound Medical has a consensus target price of $31.4167, indicating a potential upside of 67.64%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Cardiovascular Systems.

Risk and Volatility

Cardiovascular Systems has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Summary

Cardiovascular Systems beats Profound Medical on 8 of the 15 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Alphatec and Profound Medical's revenue, earnings per share (EPS) and valuation.

Profound Medical has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

31.8% of Alphatec shares are held by institutional investors. Comparatively, 35.9% of Profound Medical shares are held by institutional investors. 28.2% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Alphatec and Profound Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Alphatec and Profound Medical, as provided by MarketBeat.com.

Alphatec presently has a consensus target price of $15.4286, indicating a potential downside of 3.09%. Profound Medical has a consensus target price of $31.4167, indicating a potential upside of 67.64%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Alphatec.

Risk and Volatility

Alphatec has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Summary

Profound Medical beats Alphatec on 8 of the 15 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Valuation & Earnings

This table compares Pulmonx and Profound Medical's top-line revenue, earnings per share and valuation.

Profound Medical has lower revenue, but higher earnings than Pulmonx.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pulmonx and Profound Medical, as reported by MarketBeat.

Pulmonx currently has a consensus price target of $58.00, indicating a potential upside of 37.83%. Profound Medical has a consensus price target of $31.4167, indicating a potential upside of 67.64%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Pulmonx.

Insider & Institutional Ownership

35.9% of Profound Medical shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Pulmonx and Profound Medical's net margins, return on equity and return on assets.

Summary

Profound Medical beats Pulmonx on 6 of the 11 factors compared between the two stocks.

Profound Medical (NASDAQ:PROF) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

Profound Medical has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Profound Medical and MiMedx Group, as provided by MarketBeat.com.

Profound Medical presently has a consensus target price of $31.4167, indicating a potential upside of 67.64%. MiMedx Group has a consensus target price of $20.00, indicating a potential upside of 84.67%. Given MiMedx Group's higher possible upside, analysts clearly believe MiMedx Group is more favorable than Profound Medical.

Earnings & Valuation

This table compares Profound Medical and MiMedx Group's gross revenue, earnings per share and valuation.

Profound Medical has higher earnings, but lower revenue than MiMedx Group.

Institutional & Insider Ownership

35.9% of Profound Medical shares are owned by institutional investors. Comparatively, 4.0% of MiMedx Group shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Profound Medical and MiMedx Group's net margins, return on equity and return on assets.

Summary

Profound Medical beats MiMedx Group on 8 of the 14 factors compared between the two stocks.

Profound Medical (NASDAQ:PROF) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

Profound Medical has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Profound Medical and Atrion, as provided by MarketBeat.com.

Profound Medical presently has a consensus target price of $31.4167, indicating a potential upside of 67.64%. Given Profound Medical's higher possible upside, analysts clearly believe Profound Medical is more favorable than Atrion.

Earnings & Valuation

This table compares Profound Medical and Atrion's gross revenue, earnings per share and valuation.

Atrion has higher revenue and earnings than Profound Medical.

Institutional & Insider Ownership

35.9% of Profound Medical shares are owned by institutional investors. Comparatively, 63.2% of Atrion shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Profound Medical and Atrion's net margins, return on equity and return on assets.

Summary

Atrion beats Profound Medical on 8 of the 13 factors compared between the two stocks.

Profound Medical (NASDAQ:PROF) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

Profound Medical has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Profound Medical and SI-BONE, as provided by MarketBeat.com.

Profound Medical presently has a consensus target price of $31.4167, indicating a potential upside of 67.64%. SI-BONE has a consensus target price of $33.20, indicating a potential downside of 0.78%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than SI-BONE.

Earnings & Valuation

This table compares Profound Medical and SI-BONE's gross revenue, earnings per share and valuation.

Profound Medical has higher earnings, but lower revenue than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

35.9% of Profound Medical shares are owned by institutional investors. Comparatively, 65.3% of SI-BONE shares are owned by institutional investors. 15.5% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Profound Medical and SI-BONE's net margins, return on equity and return on assets.

Summary

Profound Medical beats SI-BONE on 9 of the 15 factors compared between the two stocks.